Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/association-of-cerebrospinal-fluid-neurofilament-light-protein-with-10Dlgv9F8w
References (36)
-
C. Jack, D. Bennett, K. Blennow, M. Carrillo, B. Dunn, S. Haeberlein, D. Holtzman, W. Jagust, F. Jessen, J. Karlawish, E. Liu, J. Molinuevo, T. Montine, C. Phelps, K. Rankin, C. Rowe, P. Scheltens, E. Siemers, H. Snyder, R. Sperling (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s diseaseAlzheimer's & dementia : the journal of the Alzheimer's Association, 14
-
Cynthia Crowson, E. Atkinson, T. Therneau (2016)
Assessing calibration of prognostic risk scoresStatistical Methods in Medical Research, 25
-
N. Norgren, L. Rosengren, T. Stigbrand (2003)
Elevated neurofilament levels in neurological diseasesBrain Research, 987
-
L. Gaetani, K. Höglund, L. Parnetti, Fani Pujol-Calderón, Bruno Becker, P. Eusebi, P. Sarchielli, P. Calabresi, M. Filippo, H. Zetterberg, K. Blennow (2018)
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluationAlzheimer's Research & Therapy, 10
-
P. Lewczuk, P. Riederer, S. O'Bryant, M. Verbeek, B. Dubois, P. Visser, K. Jellinger, S. Engelborghs, A. Ramírez, L. Parnetti, C. Jack, C. Teunissen, H. Hampel, A. Lleó, F. Jessen, Lidia Glodzik, M. Leon, A. Fagan, J. Molinuevo, Willemijn Jansen, B. Winblad, L. Shaw, U. Andreasson, M. Otto, B. Mollenhauer, J. Wiltfang, M. Turner, I. Zerr, R. Handels, Alexander Thompson, G. Johansson, Natalia Ermann, J. Trojanowski, Ilker Karaca, H. Wagner, Patrick Oeckl, Linda Doorn, M. Bjerke, D. Kapogiannis, H. Kuiperij, L. Farotti, Yi Li, B. Gordon, S. Epelbaum, S. Vos, C. Klijn, W. Nostrand, C. Minguillón, M. Schmitz, C. Gallo, A. Mato, F. Thibaut, S. Lista, D. Alcolea, H. Zetterberg, K. Blennow, J. Kornhuber, P. Riederer, Carla Gallo, D. Kapogiannis, A. Mato, F. Thibaut (2017)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological PsychiatryThe world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 19
-
Peder Buchhave, L. Minthon, H. Zetterberg, Å. Wallin, K. Blennow, O. Hansson (2012)
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.Archives of general psychiatry, 69 1
-
Hoffman (1987)
Neurofilament gene expression: a major determinant of axonal caliber.Proc Natl Acad Sci U S A, 84
-
M. Kester, C. Teunissen, D. Crimmins, Elizabeth Herries, J. Ladenson, P. Scheltens, W. Flier, J. Morris, D. Holtzman, A. Fagan (2015)
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.JAMA neurology, 72 11
-
K. Blennow, H. Hampel, M. Weiner, H. Zetterberg (2010)
Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseNature Reviews Neurology, 6
-
St Sauver (2012)
Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.Int J Epidemiol, 41
-
H. Zetterberg (2018)
Tauomics and Kinetics in Human Neurons and Biological FluidsNeuron, 97
-
R. Roberts, Y. Geda, D. Knopman, R. Cha, V. Pankratz, B. Boeve, R. Ivnik, E. Tangalos, R. Petersen, W. Rocca (2008)
The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample CharacteristicsNeuroepidemiology, 30
-
Henrietta Wellington, R. Paterson, E. Portelius, Ulrika Törnqvist, N. Magdalinou, Nick Fox, K. Blennow, J. Schott, H. Zetterberg (2016)
Increased CSF neurogranin concentration is specific to Alzheimer diseaseNeurology, 86
-
Tobias Skillbäck, Christoffer Rosén, F. Asztely, N. Mattsson, K. Blennow, H. Zetterberg (2014)
Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry.JAMA neurology, 71 4
-
Argonde Harten, L. Smits, C. Teunissen, P. Visser, T. Koene, M. Blankenstein, P. Scheltens, W. Flier (2013)
Preclinical AD predicts decline in memory and executive functions in subjective complaintsNeurology, 81
-
R. Hu (2003)
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) -
E. Portelius, H. Zetterberg, Tobias Skillbäck, Ulrika Törnqvist, U. Andreasson, J. Trojanowski, M. Weiner, L. Shaw, N. Mattsson, K. Blennow (2015)
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.Brain : a journal of neurology, 138 Pt 11
-
N. Mattsson, Philip Insel, S. Palmqvist, E. Portelius, H. Zetterberg, M. Weiner, K. Blennow, O. Hansson (2016)
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's diseaseEMBO Molecular Medicine, 8
-
Alison Headley, Andrés León-Benedetti, C. Dong, B. Levin, D. Loewenstein, C. Camargo, T. Rundek, H. Zetterberg, K. Blennow, C. Wright, Xiaoyan Sun (2018)
Neurogranin as a predictor of memory and executive function decline in MCI patientsNeurology, 90
-
P. Hoffman, D. Cleveland, J. Griffin, Phillip Landes, N. Cowan, D. Price (1987)
Neurofilament gene expression: a major determinant of axonal caliber.Proceedings of the National Academy of Sciences of the United States of America, 84 10
-
R. Ivnik, J. Malec, Glenn Smith, E. Tangalos, R. Petersen, E. Kokmen, L. Kurland (1992)
Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97Clinical Neuropsychologist, 6
-
W. Rocca, B. Yawn, B. Yawn, J. Sauver, B. Grossardt, L. Melton (2012)
History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.Mayo Clinic proceedings, 87 12
-
M. Charlson, P. Pompei, Kathy Ales, C. MacKenzie (1987)
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.Journal of chronic diseases, 40 5
-
Hlin Kvartsberg, E. Portelius, U. Andreasson, G. Brinkmalm, K. Hellwig, Natalia Lelental, J. Kornhuber, O. Hansson, L. Minthon, P. Spitzer, J. Maler, H. Zetterberg, K. Blennow, P. Lewczuk (2015)
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controlsAlzheimer's Research & Therapy, 7
-
I. Rossum, S. Vos, L. Burns, D. Knol, P. Scheltens, H. Soininen, L. Wahlund, H. Hampel, M. Tsolaki, L. Minthon, G. L’italien, W. Flier, C. Teunissen, K. Blennow, F. Barkhof, D. Rueckert, R. Wolz, F. Verhey, P. Visser (2012)
Injury markers predict time to dementia in subjects with MCI and amyloid pathologyNeurology, 79
-
Gaetani (2018)
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.Alzheimers Res Ther, 10
-
S. Vos, C. Xiong, P. Visser, Mateusz Jasielec, J. Hassenstab, E. Grant, N. Cairns, J. Morris, D. Holtzman, A. Fagan (2013)
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort studyThe Lancet Neurology, 12
-
Kvartsberg (2015)
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer?s disease patients and healthy controls.Alzheimers Res Ther, 7
-
Roe (2013)
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.Neurology, 80
-
O. Okonkwo, M. Alosco, H. Griffith, M. Mielke, L. Shaw, J. Trojanowski, G. Tremont, G. Tremont (2010)
Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.Archives of neurology, 67 6
-
R. Petersen (2004)
Mild cognitive impairment as a diagnostic entityJournal of Internal Medicine, 256
-
P. Scheltens, K. Blennow, M. Breteler, B. Strooper, G. Frisoni, S. Salloway, W. Flier (2016)
Alzheimer's diseaseThe Lancet, 388
-
H. Zetterberg, Tobias Skillbäck, N. Mattsson, J. Trojanowski, E. Portelius, L. Shaw, M. Weiner, K. Blennow (2016)
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.JAMA neurology, 73 1
-
J. Pereira, E. Westman, O. Hansson (2017)
Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's diseaseNeurobiology of Aging, 58
-
C. Roe, A. Fagan, E. Grant, J. Hassenstab, K. Moulder, D. Dreyfus, C. Sutphen, T. Benzinger, M. Mintun, D. Holtzman, J. Morris (2013)
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years laterAlzheimer's & Dementia, 9
-
E. Portelius, B. Olsson, K. Höglund, N. Cullen, Hlin Kvartsberg, U. Andreasson, H. Zetterberg, Å. Sandelius, L. Shaw, V. Lee, D. Irwin, M. Grossman, D. Weintraub, A. Chen-Plotkin, D. Wolk, L. McCluskey, L. Elman, Jennifer McBride, J. Toledo, J. Trojanowski, K. Blennow (2018)
Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathologyActa Neuropathologica, 136
- Publisher
- American Medical Association
- Copyright
- Copyright 2018 American Medical Association. All Rights Reserved.
- ISSN
- 2168-6149
- eISSN
- 2168-6157
- DOI
- 10.1001/jamaneurol.2018.3459
- Publisher site
- See Article on Publisher Site
Abstract
Key PointsQuestionAre cerebrospinal fluid (CSF) neurofilament light protein (NfL) and neurogranin (Ng) levels associated with the risk of incident mild cognitive impairment (MCI), and how do these markers compare with CSF total (T-tau) or phosphorylated tau (P-tau) for risk of MCI in the general community? FindingsIn this population-based study, compared with the bottom quartile, the top quartile of CSF NfL was associated with a 3-fold increased risk of MCI. Neither CSF T-tau, P-tau, nor Ng levels were associated with risk of MCI. MeaningElevated CSF NfL levels, but not T-tau, P-tau, or Ng levels, are associated with risk of MCI in a community population.
Journal
JAMA Neurology – American Medical Association
Published: Feb 12, 2019